Alexa J Hughes, Kristen N Kaiser, Emma Holler, Brian M Ruedinger, Anita A Turk, Cary Jo R Schlick, Michael G House, Karl Y Bilimoria, Ryan J Ellis
{"title":"前往大容量医院治疗胰腺腺癌患者的护理碎片化与辅助化疗递送之间的关系","authors":"Alexa J Hughes, Kristen N Kaiser, Emma Holler, Brian M Ruedinger, Anita A Turk, Cary Jo R Schlick, Michael G House, Karl Y Bilimoria, Ryan J Ellis","doi":"10.1245/s10434-025-18539-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Surgical care for pancreatic ductal adenocarcinoma (PDAC) is increasingly centralized to high-volume hospitals (HVHs), prompting many patients to travel farther for resection. While surgery is centralized, adjuvant chemotherapy is often delivered locally, resulting in care fragmentation. The implications of this separation on chemotherapy receipt and survival are unclear. This study evaluated associations between travel distance, care fragmentation, and receipt of adjuvant chemotherapy in patients undergoing upfront PDAC resection at HVHs and assessed how these factors influenced overall survival.</p><p><strong>Methods: </strong>Patients with non-metastatic PDAC who underwent upfront resection at HVHs (≥20 pancreatectomies/year) were identified from the National Cancer Database (2007-2021). The cohort was stratified by adjuvant chemotherapy receipt, travel distance (deciles D1-D10), and care fragmentation. Multivariable logistic regression assessed factors associated with chemotherapy receipt; Cox proportional hazards models evaluated survival.</p><p><strong>Results: </strong>Among 17,807 patients treated at 97 HVHs, 10,200 (57%) received adjuvant chemotherapy. Patients traveling ≥14 miles (≥D4) were less likely to receive adjuvant chemotherapy (D4 odds ratio [OR] 0.85; 95% confidence interval [CI] 0.73-0.99; P=0.04). Patients experiencing care fragmentation were more likely to receive adjuvant therapy (64.3% vs. 54.4%, OR 1.51; 95% CI 1.35-1.69; P<0.001). Travel ≥20 miles (≥D5) was associated with higher mortality (hazards ratio [HR] 1.12; 95% CI 1.02-1.23; P=0.01). Conversely, receipt of adjuvant chemotherapy (HR 0.77; 95% CI 0.73-0.81; P<0.001) and fragmented care (HR 0.89; 95% CI 0.84-0.93; P<0.001) were associated with improved survival.</p><p><strong>Conclusions: </strong>Longer travel distance was associated with lower chemotherapy receipt and worse survival. Care fragmentation was linked to improved treatment access and survival, underscoring the need for coordinated cross-institutional care.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma.\",\"authors\":\"Alexa J Hughes, Kristen N Kaiser, Emma Holler, Brian M Ruedinger, Anita A Turk, Cary Jo R Schlick, Michael G House, Karl Y Bilimoria, Ryan J Ellis\",\"doi\":\"10.1245/s10434-025-18539-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Surgical care for pancreatic ductal adenocarcinoma (PDAC) is increasingly centralized to high-volume hospitals (HVHs), prompting many patients to travel farther for resection. While surgery is centralized, adjuvant chemotherapy is often delivered locally, resulting in care fragmentation. The implications of this separation on chemotherapy receipt and survival are unclear. This study evaluated associations between travel distance, care fragmentation, and receipt of adjuvant chemotherapy in patients undergoing upfront PDAC resection at HVHs and assessed how these factors influenced overall survival.</p><p><strong>Methods: </strong>Patients with non-metastatic PDAC who underwent upfront resection at HVHs (≥20 pancreatectomies/year) were identified from the National Cancer Database (2007-2021). The cohort was stratified by adjuvant chemotherapy receipt, travel distance (deciles D1-D10), and care fragmentation. Multivariable logistic regression assessed factors associated with chemotherapy receipt; Cox proportional hazards models evaluated survival.</p><p><strong>Results: </strong>Among 17,807 patients treated at 97 HVHs, 10,200 (57%) received adjuvant chemotherapy. Patients traveling ≥14 miles (≥D4) were less likely to receive adjuvant chemotherapy (D4 odds ratio [OR] 0.85; 95% confidence interval [CI] 0.73-0.99; P=0.04). Patients experiencing care fragmentation were more likely to receive adjuvant therapy (64.3% vs. 54.4%, OR 1.51; 95% CI 1.35-1.69; P<0.001). Travel ≥20 miles (≥D5) was associated with higher mortality (hazards ratio [HR] 1.12; 95% CI 1.02-1.23; P=0.01). Conversely, receipt of adjuvant chemotherapy (HR 0.77; 95% CI 0.73-0.81; P<0.001) and fragmented care (HR 0.89; 95% CI 0.84-0.93; P<0.001) were associated with improved survival.</p><p><strong>Conclusions: </strong>Longer travel distance was associated with lower chemotherapy receipt and worse survival. Care fragmentation was linked to improved treatment access and survival, underscoring the need for coordinated cross-institutional care.</p>\",\"PeriodicalId\":8229,\"journal\":{\"name\":\"Annals of Surgical Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Surgical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1245/s10434-025-18539-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-025-18539-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:胰腺导管腺癌(PDAC)的手术治疗越来越集中于大容量医院(HVHs),这促使许多患者到更远的地方进行切除。虽然手术是集中的,但辅助化疗往往是局部进行的,导致护理碎片化。这种分离对化疗接受和生存的影响尚不清楚。本研究评估了在HVHs接受前期PDAC切除术的患者的旅行距离、护理碎片化和接受辅助化疗之间的关系,并评估了这些因素如何影响总生存期。方法:从国家癌症数据库(2007-2021)中确定在HVHs进行前期切除术(≥20例胰腺切除术/年)的非转移性PDAC患者。该队列根据辅助化疗的接受情况、行进距离(D1-D10十分位数)和治疗碎片性进行分层。多变量logistic回归评估化疗接受度相关因素;Cox比例风险模型评估生存率。结果:在97个HVHs治疗的17807例患者中,10200例(57%)接受了辅助化疗。旅行≥14英里(≥D4)的患者接受辅助化疗的可能性较小(D4优势比[OR] 0.85; 95%可信区间[CI] 0.73-0.99; P=0.04)。经历护理碎片化的患者更有可能接受辅助治疗(64.3% vs. 54.4%, OR 1.51; 95% CI 1.35-1.69; p)结论:较长的旅行距离与较低的化疗接受率和较差的生存率相关。护理碎片化与改善治疗可及性和生存率有关,强调了协调跨机构护理的必要性。
Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma.
Background: Surgical care for pancreatic ductal adenocarcinoma (PDAC) is increasingly centralized to high-volume hospitals (HVHs), prompting many patients to travel farther for resection. While surgery is centralized, adjuvant chemotherapy is often delivered locally, resulting in care fragmentation. The implications of this separation on chemotherapy receipt and survival are unclear. This study evaluated associations between travel distance, care fragmentation, and receipt of adjuvant chemotherapy in patients undergoing upfront PDAC resection at HVHs and assessed how these factors influenced overall survival.
Methods: Patients with non-metastatic PDAC who underwent upfront resection at HVHs (≥20 pancreatectomies/year) were identified from the National Cancer Database (2007-2021). The cohort was stratified by adjuvant chemotherapy receipt, travel distance (deciles D1-D10), and care fragmentation. Multivariable logistic regression assessed factors associated with chemotherapy receipt; Cox proportional hazards models evaluated survival.
Results: Among 17,807 patients treated at 97 HVHs, 10,200 (57%) received adjuvant chemotherapy. Patients traveling ≥14 miles (≥D4) were less likely to receive adjuvant chemotherapy (D4 odds ratio [OR] 0.85; 95% confidence interval [CI] 0.73-0.99; P=0.04). Patients experiencing care fragmentation were more likely to receive adjuvant therapy (64.3% vs. 54.4%, OR 1.51; 95% CI 1.35-1.69; P<0.001). Travel ≥20 miles (≥D5) was associated with higher mortality (hazards ratio [HR] 1.12; 95% CI 1.02-1.23; P=0.01). Conversely, receipt of adjuvant chemotherapy (HR 0.77; 95% CI 0.73-0.81; P<0.001) and fragmented care (HR 0.89; 95% CI 0.84-0.93; P<0.001) were associated with improved survival.
Conclusions: Longer travel distance was associated with lower chemotherapy receipt and worse survival. Care fragmentation was linked to improved treatment access and survival, underscoring the need for coordinated cross-institutional care.
期刊介绍:
The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.